Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Filings indexed 1,490 across all filing types
Latest filing 2024-03-27 Annual Report
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 100% confidence The document is titled 'FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023' and contains detailed consolidated financial statements including profit or loss, comprehensive income, and financial position for the full fiscal year ending December 31, 2023. It includes notes on basis of preparation, changes in accounting policies, segment information, and detailed financial data. The length is substantial (15,000 characters) and the content is comprehensive, indicating this is the full annual financial report rather than a brief announcement or summary. The presence of full financial statements and detailed notes aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification, so it is not RPA or RNS. Therefore, the document is classified as an Annual Report (10-K).
2024-03-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by 3SBio Inc. It includes detailed information about repurchase of shares, dates, prices, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activity and capital changes rather than financial results, management changes, or regulatory certifications. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is sufficient and contains substantive data about the share repurchase event, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-03-27 English
PROPOSED SHARE REPURCHASE
Transaction in Own Shares Classification · 95% confidence The document is an announcement by 3SBio Inc. regarding its intention to repurchase shares under existing and upcoming repurchase mandates. It references previous circulars and mandates granted at annual general meetings but does not contain financial statements or detailed financial data. The document is relatively short (3808 characters) and serves as a notification of a proposed share repurchase plan rather than the repurchase activity itself or a detailed financial report. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements about share repurchase plans or activities.
2024-03-21 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Final Dividend for the year ended 31 December 2023' and contains detailed information about the dividend amount, payment dates, record dates, ex-dividend dates, and shareholder approval date. It is an announcement specifically about the dividend payment for the financial year ended 2023. The document length is 3577 characters, which is relatively short and focused solely on dividend details. There is no financial statement or comprehensive report content, only dividend-related information. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2024-03-20 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023' and contains detailed consolidated financial statements including profit or loss, comprehensive income, financial position, and notes to the financial statements. It includes extensive financial data and analysis for the full fiscal year ending December 31, 2023. The length of the document is 15,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an Annual Report, which covers company activity and full financial performance for the year. Therefore, the document should be classified as an Annual Report (10-K).
2024-03-20 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the Board of Directors of Hongkong Chinese Limited about the date of a forthcoming board meeting. The purpose of the meeting includes approving the consolidated final results for the year ended 31 December 2023 and considering a final dividend. The document does not contain any financial data or the actual report but merely announces the meeting date and agenda. The document length is short (1618 characters) and it explicitly states the meeting will approve the final results, indicating the report itself is not included here. According to the rules, such announcements about meeting dates and agenda are classified as Regulatory Filings (RNS) because they do not contain the actual report or financial data, nor are they a report publication announcement since it does not mention the report is attached or published.
2024-03-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.